UNSPSC 51384004: Morazone hydrochloride

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C23H27N3O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EFJ5QS2AU5, chemically known as antipyrine, 4-(4-(3-methyl-2-phenylmorpholino)methyl)-, hydrochloride but more generally known as morazone hydrochloride, which bears US NIH Compound Identifier 39608. European Medicines Agency schedules Morazone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03329MIG.

Most nations, for tariff and trade purposes, schedule morazone hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, MORAZONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC1C(C(=O)N(N1C)C2CCCCC2)CN3CCOC(C3C)C4CCCCC4.CL.

UNSPSC 51384004 Morazone hydrochloride is a Commodity code that shows minimal recent state and local procurement activity aligned with its nominal scope. The three most recent opportunities posted under this code involve naloxone procurement, direct-to-manufacturer pharmacy initiatives, and generic multi-source pharmaceuticals — none of which constitute morazone hydrochloride sourcing. State and local governments are not actively soliciting this specific pharmaceutical ingredient through recent RFPs, RFQs, or IFBs; the code appears to be either underutilized or misapplied to adjacent pharmaceutical categories in current procurement workflows.

The issuing bodies represented in recent activity span county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving state and local government facilities across participating states including Oregon). Geographic reach includes Florida, Texas, and Minnesota-based consortia, though activity remains sparse and tangential to morazone hydrochloride itself. The single concrete opportunity closest to pharmaceutical manufacturing is the MMCAP Generic Multi Source Pharmaceuticals RFP (S1070000015802), issued by the Minnesota Department of Administration on January 20, 2026 with a March 26, 2026 response deadline, which seeks generic pharmaceutical manufacturers with cGMP certification and Drug Supply Chain Security Act compliance for supply through authorized wholesalers — but this RFP targets broad generic and OTC product categories rather than morazone specifically. For vendors targeting this code, activity warrants close monitoring; current procurement does not demonstrate active demand for this particular pharmaceutical ingredient at the state and local level.